GSTM1 and paroxysmal nocturnal hemoglobinuria: The ERG was satisfied that if the efficacy of ravulizumab was equal to the efficacy of eculizumab for patients with PNH who have baseline Hb levels < 10.5 g/dL despite treatment with a stable dose of a C5 inhibitor for ≥ 3 months, the most plausible ICERs per QALY gained for the comparisons of pegcetacoplan versus eculizumab and pegcetacoplan versus ravulizumab were < £20,000 and therefore met the NICE low ICER FTA criteria.